Researchers have found that several kinase inhibitors produce many more Induced Pluripotent Stem Cells (iPSCs) than untreated cells, in some cases too many iPSCs for the tiny dish housing them. The most potent inhibitors targeted three kinases in particular: AurkA, P38, and IP3K.
Induced Pluripoent Stem Cells hold promise as autologous and allogeneic therapeutic solutions. Perhaps even more importantly they can be produced from the adult cells of diseased individuals thus providing a perfect medium for the study of debilitating diseases. Issues regarding their use either in the laboratory or therapeutically involve both expansion methods and cost. This new research suggests solutions to both.
Stem Cell Digest postings on induced pluripotent stem cells include:
- Cedars-Sinai iPSC Core Production Facility
- iPSC Therapies Could Encounter Immune Rejection Problems
- Category: Induced Pluripotent Stem Cells
See the Sanford-Burnham Research Institute announcement.
Comments